1. Home
  2. RGNT vs CVKD Comparison

RGNT vs CVKD Comparison

Compare RGNT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$3.28

Market Cap

20.4M

Sector

Health Care

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$7.40

Market Cap

19.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGNT
CVKD
Founded
2004
2022
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.4M
19.0M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RGNT
CVKD
Price
$3.28
$7.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$32.00
AVG Volume (30 Days)
6.0K
50.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$4.91
52 Week High
$8.35
$20.39

Technical Indicators

Market Signals
Indicator
RGNT
CVKD
Relative Strength Index (RSI) 29.00 50.25
Support Level N/A $6.64
Resistance Level $4.40 $8.87
Average True Range (ATR) 0.24 0.65
MACD 0.03 -0.03
Stochastic Oscillator 13.46 31.46

Price Performance

Historical Comparison
RGNT
CVKD

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: